Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-03-16
2010-10-26
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S254020, C514S322000, C514S366000, C544S132000, C544S133000, C544S368000, C546S199000, C548S151000
Reexamination Certificate
active
07820657
ABSTRACT:
Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.
REFERENCES:
patent: 3210370 (1965-10-01), Ursprung
patent: 3267112 (1966-08-01), Iwai et al.
patent: 3507854 (1970-04-01), Sumagawa et al.
patent: 4354970 (1982-10-01), Fleischer et al.
patent: 4464384 (1984-08-01), Murase et al.
patent: 4497817 (1985-02-01), Murase et al.
patent: 4880824 (1989-11-01), Press et al.
patent: 5236952 (1993-08-01), Bernauer et al.
patent: 5466706 (1995-11-01), George et al.
patent: 5623073 (1997-04-01), Anisimova et al.
patent: 5639756 (1997-06-01), Anisimova et al.
patent: 5919799 (1999-07-01), Tasaka et al.
patent: 6696441 (2004-02-01), Cottam et al.
patent: 7153873 (2006-12-01), Gerlach et al.
patent: 2004/0067991 (2004-04-01), Greig et al.
patent: 2004/0127719 (2004-07-01), Yang et al.
patent: 2005/0074632 (2005-04-01), Lee et al.
patent: 2005/0165024 (2005-07-01), Milanov et al.
patent: 2006/0122178 (2006-06-01), Cottam et al.
patent: 2009/0123418 (2009-05-01), James
patent: 2009/0131426 (2009-05-01), Bhagwat et al.
patent: 524 055 (1993-01-01), None
patent: 1 029 854 (2000-01-01), None
patent: 1 047 418 (2005-07-01), None
patent: 2699920 (1994-07-01), None
patent: 2700546 (1994-07-01), None
patent: 2722501 (1996-01-01), None
patent: 2759698 (1998-08-01), None
patent: 56138196 (1981-10-01), None
patent: 57040492 (1982-03-01), None
patent: 57149288 (1982-09-01), None
patent: 05107705 (1993-04-01), None
patent: 7291976 (1996-07-01), None
patent: 11-106340 (1999-04-01), None
patent: 2001048786 (2001-02-01), None
patent: 2001192386 (2001-07-01), None
patent: WO98/06724 (1998-02-01), None
patent: WO99/40094 (1999-08-01), None
patent: WO00/78726 (2000-12-01), None
patent: WO 01/27119 (2001-04-01), None
patent: WO 03/031587 (2003-04-01), None
patent: WO2004/048368 (2004-06-01), None
patent: WO2004/058758 (2004-07-01), None
Byrn et al. Solid-State Chemistry of Drugs, 2d, Chapter 11 Hydrates and Solvates, 233-247, 233.
Morissette et al. Adv. Drug Delivery Rev. 2004, 56, 275-300.
A.M. Rouhi, Chem. & Eng. News, Feb. 24, 2003, 81(8), 32-35.
Abignente, et al., “Research on heterocyclic compounds-V,”Il Farmaco Edizione Scientifica(1976), vol. 31, fasc. 12, 880-887.
Achen, et al., “Targeting lymphangiogenesis to prevent tumor metastasis,”British Journal of Cancer(2006) 94, 1355-1360.
Anisimova, et al., “Imidazo[1,2-a] benzimidazole derivatives, X Nitration of 2,9-disubstituted imidazo [1,2-a] benzimidazole,” (1975),Khimiya Geterotsiklicheskikh Soedinenii, 258-62.
Bergers, et al., “Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors,” (2003),Journal of Clinical Investigation, vol. 111, No. 9, 1287-1295.
Blume-Jensen, et al., “Oncogenic kinase signalling,” (2001),Naturevol. 411, 355-365.
Carlomagno, et al., “BAY 43-9006 Inhibition of Oncogenic RET Mutants,” (2006),Journal of the National Cancer Institute, vol. 98, No. 5, 326-334.
Chernovyants, et al., Spectrochemical characteristics of symmetrical monomethinecyanines based on pyrrolo- and imidazo [1,2-a] benzimidazole,Urainskii Khimicheskii Zhurnal, (1992), 58(3), 257-61.
Cools, et al., “A Tyrosine Kinase Created by Fusion of the PDGFRA and FIPILI Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome,” (2003),The New England Journal of Medicine, vol. 348, No. 13, 1201-1214.
Curtin, et al., “Somatic Activation of KIT in Distinct Subtypes of Melanoma,” (2006)Journal of Clinical Oncology, vol. 24, No. 26, 4340-4346.
Duensing, et al., “Biology of Gastrointestinal Stromal Tumors: KIT Mutations and Beyond,” (2004)Cancer Investigationvol. 22, No. 1, 106-116.
Fabian, et al., “A small molecule-kinase interation map for clinical kinase inhibitors,” (2005)Nature Biotechnology, vol. 23, No. 3, 329-336.
Gazit, et al., “Tyrphostins. 5. Potent Inhibitors of Platelet-Drived Growth Factor Receptor Tyrosine Kinase: Structure-Activity Relationships in Quinoxalines, Quinolines, and Indole Tyrphostins,” (1996)J. Med. Chem, 39, 2170-2177.
De Giorgi, et al., “Imatinib and gastrointestinal stromal tumors: Where do we go from here?,” (2005)Mol Cancer Ther4 (3), 495-501.
Glickman, et al., “A Comparison of ALPHAScreen, TR-FRET, and TRF as Assay Methods for FXR Nuclear Receptors,” (2002) Journal of Biomolecular Screening, vol. 7, No. 1, 8 pages.
Grin, et al., “Investigations in the imidazole series LXXVIII. Reaction of 2-aminobenzothiazoles with a-Halo Ketones,” (1972)Khimiya Geterotsiklicheskikh Soedinenii, 1271-4.
Haran-Ghera, et al., “Increased Circulating Colony-Stimulating Factor-1 (CSF-1) in SJL/J Mice with Radiation-Induced Acute Myeloid Leukemia (AML) is Associated With Autocrine Regulation of AML Cells by CSF-1,” (1997)Blood, vol. 89, No. 7. 2537-2545.
Heinrich, et al., “PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors,” (2003)Science, vol. 299, 708-710.
Heinrich, “Targeting FLT3 Kinase in Acute Myelogenous Leukemia: Progress, Perils, and Prospects,” (2004)Mini-Reviews in Medicinal Chemistry, vol. 4, 255-271.
Kacinski, “CSF-1 and Its Receptor in Breast Carcinomas and Neoplasms of the Female Reproductive Tract,” (1997)Molecular Reproduction and Development, 46:71-74.
Kiyoi, et al., “Clinical Significance of FLT3 in Leukemia,” (2005)International Journal of Hematology, vol. 82, No. 2, 85-92.
Kohn, et al., “Cell Cycle Control and Cancer Chemotherapy,” (1994)Journal of Cellular Biochemistry, 54:440-452.
Krasovskii, et al., Synthesis and properties of naphtha[1,2-d]thiazolo[3,2-a]imidazole derivatives,Farmatsevtichnii Zhurnal(Kiev), (1977) (5), 83-4.
Krause, et al., “Tyrosine Kinases as Targets for Cancer Therapy,” (2005)New England Journal of Medicine353;2, 172-187.
Kumabe, et al., “Amplification of x-platelet-derived growth factor receptor gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin,” (1992)Oncogene, 7, 627-633.
Levis, et al., “FLT3 Tyrosine Kinase Inhibitors,” (2005)International Journal of Hematology, vol. 82, No. 2, 100-107.
Magnusson, et al., “Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor B receptor fusion oncogene,” (2002)Blood, vol. 100, No. 3, 1088-1091.
Ostman, et al., “Involvement of Platelet-Derived Growth Factor in Disease: Development of Specific Antagonists,” (2001)Cancer Research, vol. 80, 1-38.
Mase, et al., “Imidazo[2,1-b]benzothiazoles. 2.1 New Immunosuppressive Agents,”J. Med. Chem(1986) 29, 386-394.
Patra, et al., “Derivatives of Imidazole,”J. Indian Chem. Soc., vol. LI, (1974) 1031-1034.
Paz, et al., “Development of Angiogenesis Inhibitors to Vascular Endothelial Growth Factor Receptor 2. Current Status and Future Perspective,” (2005)Fronters in Bioscience, 10, 1415-1439.
Pentimalli, “Substitution and addition reactions of benzo-substituted 2-phenylimidazo [2,1-b] benzothiazoles,” (1969)Gazzetta Chimica Italiana, 99(4), 362-72, CODEN: GCITA9; ISSN: 0016-5603.
Pietras, et al., “PDGF receptors as cancer drug targets,” (2003)Cancer Cell, vol. 3, 439-443.
Pietras, et al., “Inhibition of PDGF Receptor Signaling in Tumor Stroma Enhances Antitumor Effect of Chemotherapy,” (2002)Cancer Research, 62, 5476-5484.
Plowman, et al., “Receptor Tyrosine Kinases as Targets for Drug Intervention,” (1994)Drug News and Perspectives, vol. 7, No. 6, 334-339.
Rolland, et al., “Increased Blood Myeloid Dendritic Cells and Dendritic Cell-Poietins in Langerhans Cell Histiocytosis,” (2005)The Journal of Immunology, 174: 3067-3071.
Saharinen, et al., &#
Bhagwat Shripad
Chao Qi
Grotzfeld Robert M.
Patel Hitesh K.
Sprankle Kelly G.
Ambit Biosciences Corporation
Anderson Rebecca L
Jones Day
Nolan Jason M
LandOfFree
Imidazolothiazole compounds for the treatment of disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazolothiazole compounds for the treatment of disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazolothiazole compounds for the treatment of disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4234774